Lassa Fever: An Emerging and Re-emerging Fatal Viral Disease of Public Health Concern

Mahendra Pal^1, , Kirubel Paulos Gutama², Leena Gowda³ and Pratibha Dave⁴

¹Narayan Consultancy on Veterinary Public Health and Microbiology, Anand, India

²Adaba Woreda Livestock and Fishery Resource Development Office, West Arsi, Ethiopia

³Department of Veterinary Public Health and Epidemiology, College of Veterinary Science, Bangaluru, India

⁴Welfare Hospital and Research Centre, Bharuch, Gujarat, India

Cite this paper

Mahendra Pal, Kirubel Paulos Gutama, Leena Gowda and Pratibha Dave. Lassa Fever: An Emerging and Re-emerging Fatal Viral Disease of Public Health Concern. American Journal of Public Health Research. 2022; 10(4):143-146. doi: 10.12691/AJPHR-10-4-2

Abstract

Lassa fever is a life threatening infectious zoonosis of public health significance, and is caused by a single-stranded, linear, bi-segmented RNA virus belonging to the Arenaviridae family. The disease is transmitted by rodents, particularly the Natal mastomys (Mastomys natalensis). In terms of public health impact, Lassa fever outperforms Ebola, Marburg, and all other hemorrhagic fevers except Dengue. Lassa fever is endemic in Benin, Ghana, Guinea, Liberia, Mali, Sierra Leone, and Nigeria, although it is also thought to exist in other West African countries. Each year, it is thought to be responsible for up to 300,000 new infections and 5000 deaths in Western Africa. Lassa virus disease was named one of the world's top bio-threats by the global Coalition for Epidemic Preparedness (CEPI) in 2017. Humans are most typically infected through the ingestion or inhalation. Nosocomial infection is also noticed. Very recently, an outbreak of Lassa fever was confirmed in Togo. However, when symptomatic, fever, general malaise and weakness, headache, hemorrhaging (in the gums, eyes, or nose, for example), respiratory distress, frequent vomiting, face swelling, discomfort in the chest, back, and abdomen; and shock occur. Deafness is the most common complications of Lassa fever. The fatality rate in the hospitalized patients may reach 15 to 20 %. There are a variety of virus diagnostic techniques available, ranging from viral culture to serological and molecular diagnostic testing. There are currently no FDA-approved vaccinations for Lassa fever, and therapy options are exceedingly restricted. Early supportive care, such as rehydration and symptomatic treatment, improves survival prospects.

Keywords

emerging disease, Lassa fever, Lassa virus, Mastomys natalensis, public health, Western Africa, zoonosis

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Pal, M, Importance of zoonoses in public health, Indian Journal of Animal Sciences, 75:586-591, 2005
[2]	Pal, M, Public health concern due to emerging and re-emerging zoonoses, International Journal of Livestock Research, 3:56-62, 2013.
[3]	Pal, M, Zoonoses. 2nd Ed. Satyam Publishers, Jaipur, India. 2007.
[4]	Fichet-Calvet, E. and Rogers, D.J, Risk maps of Lassa fever in West Africa, PLoS Neglected Tropical Disease, 3:e388, 2009.
[5]	Frame, J.D., Baldwin, J.M., Gocke, D.J. and Troup, J.M, Lassa fever, a new virus disease of man from West Africa: Clinical description and pathological findings, American Journal of Tropical Medicine and Hygiene, 19: 670–676, 1970.
[6]	Olayemi, A., Cadar, D., Magassouba, N.F., Obadare, A., Kourouma, F., Oyeyiola, A., Fasogbon, S., Igbokwe, J., Rieger, T. and Bockholt, S, New hosts of the Lassa virus, Science Republic, 6: 25280, 2016.
[7]	Olayemi, A., Oyeyiola, A., Obadare, A., Igbokwe, J., Adesina, A.S., Onwe, F., Ukwaja, K.N., Ajayi, N.A., Rieger, T. and Gunther, S, Widespread Arenavirus occurrence and seroprevalence in small mammals in Nigeria, Parasite and Vectors, 11:416, 2018.
[8]	CDC, Lassa fever, Centers for Disease Control and Prevention, 2019. Available online: https://www.cdc.gov/vhf/ lassa/index.html.
[9]	Prescott, J.B., Marzi, A., Safronetz, D., Robertson, S.J., Feldmann, H. and Best, S.M, Immunobiology of Ebola and LASV infections, Nature Review Immunology, 17: 195, 2017.
[10]	Ibekwe T.S., Okokhere P.O., Asogun D., Blackie F.F., Nwegbu M.M., Wahab K.W., Omilabu, S.A. and Akpede G.O, Early-onset sensorineural hearing loss in Lassa fever, European Annals of Otorhino-laryngology, 268:197–201, 2011.
[11]	Richmond J.K. and Baglole D.J, Lassa fever: Epidemiology, clinical features, and social consequences, British Medical Journal, 327:1271-1275, 2003.
[12]	WHO, Emergencies Preparedness, Response Lassa fever, World Health Organization, 2019. Available online: https://www.who.int/csr/don/archive/disease/lassa_fever/en/.
[13]	McCormick, J.B., King, I.J., Webb, P.A., Scribner, C.L., Craven, R.B., Johnson, K.M., Elliott, L.H. and Belmont-Williams, R, Lassa fever: Effective therapy with ribavirin, New England Journal of Medicine, 314: 20-26, 1986.
[14]	Yun, N.E. and Walker D.H, Pathogenesis of Lassa fever, Viruses, 4: 2031-2048, 2012.
[15]	Peterson, A., Townsend, M., Lina, M., Bausch, M. and Daniel, G, “Mapping transmission risk of Lassa fever in West Africa: The Importance of quality control, sampling bias, and error weighting”, PLOS ONE, 9:e100711, 2014.
[16]	Micheal, J.B., Michael, D.B. and Clarence, J P. In: Bernard N. Fields et al (eds); Fields-Virology; Lippincott Williams & Wilkins Publishers, 4th ed, 2001. Pp. 1635-1668.
[17]	Hastie, K.M., Bale, S., Kimberlin, C.R. and Saphire, E.O, Hiding the evidence: Two strategies for innate immune evasion by hemorrhagic fever viruses, Current Opinion in Virology, 2: 151-156, 2012.
[18]	Goeijenbier, M., Wagenaar, J., Goris, M., Martina, B., Henttonen, H., Vaheri, A., Reusken, C., Hartskeerl, R. and Osterhaus, A, “Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable–epidemiology, diagnostics and treatment, Critical Reviews in Microbiology, 39: 26-42, 2013.
[19]	WHO, Lassa fever, Fact sheet No 179, World Health Organization, Geneva, Switzerland, 2000.
[20]	Leski, T.A., Stockelman, M.G., Moses, L.M., Park, M., Stenger, D.A., Ansumana, R., Bausch, D.G. and Lin, B, Sequence variability and geographic distribution of LASV, Sierra Leone, Emerging Infectious Disease, 21: 609-618, 2015.
[21]	Shao, J., Liang, Y. and Ly, H, Human hemorrhagic fever causing Arenaviruses: Molecular mechanisms contributing to virus virulence and disease pathogenesis, Pathogens, 4: 283-306, 2015.
[22]	Public Health England, Lassa fever: origins, reservoirs, transmission and guidelines, 2014. Archived from https//www.gov.uk/guidance/the original.
[23]	Healing, T. and Gopal, R, Report on an assessment visit to Sierra Leone, April 12th-30th 2001, London. 2001.
[24]	Keenlyside, R.A., McCormick, J.B., Webb, P.A., Smith, E., Elliott, L. and Johnson, K.M, Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone, American Journal of Tropical Medicine and Hygiene, 32: 829-37, 1983.
[25]	David, G., Barbara, K., Eric, J. and Dziuban, J, What pediatricians should know about Lassa virus infection, Journal of American Medical Association Pediatrics, 172: 407-408, 2018.
[26]	WHO, Lassa fever fact sheet, World Health Organization Geneva, Switzerland, 2017.
[27]	CDC, 2016, Lassa Fever. Centers for Disease Control and Prevention, Available at: https://www.cdc.gov/vhf/lassa fever/.
[28]	Raabe, V. and Koehler, J, Laboratory diagnosis of Lassa fever, Journal of Clinical Microbiology, 55: 1629-1637, 2017.
[29]	WHO, WHO Calls for Early Diagnostic Tests for Lassa Fever, World Health Organization Geneva, Switzerland, 2016.
[30]	Drosten, C., Kümmerer, B.M., Schmitz, H. and Günther, S, Molecular diagnostics of viral hemorrhagic fevers, Antiviral Research, 57: 61-87, 2003.
[31]	Bausch, D.G., Rollin, P.E. and Demby, A.H, Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent antibody test, and virus isolation, Journal of clinical Microbiology, 38: 2670-2677, 2000.
[32]	Asogun, D.A., Adomeh, D.I., Ehimuan, J., Odia, I., Hass, M. and Gabriel, M, Molecular diagnostics for Lassa fever at Irrua specialist teaching hospital, Nigeria: Lessons learnt from two years of laboratory operation, PLoS Neglected Tropical Diseases, 6: e1839, 2012.
[33]	Yuil, M.T. (2021). Hanta virus Infection. MSD Veterinary Manual.
[34]	Zapata, C.J., Medina-Moreno, S., Camila, C. and Maria, S, Improving the breadth of the host’s immune response to LASV, Pathogens, 8:74-79, 2018.
[35]	Olschläger, S. and Flatz, L, Vaccination strategies against highly pathogenic Arenaviruses: The next steps toward clinical trials, PLoS Pathogen, 9:e1003212, 2013.
[36]	Vrba, S.M., Kirk, N.M., Brisse, M., Yuying Liang, Y. and Ly, H. Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats. Vaccines, 8: 860, 2020.
[37]	Fathi, A., Dahlke, C. and Addo, M.M. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Human Vaccines and Immunotherapeutics, 15: 2269-2285, 2019.
[38]	Hallam, H.J., Hallam, S., Rodriguez, S.E., Alan, D., Barrett, T., Beasley, W.C., Chua, A., Ksiazek, T.G., Milligan, N.G., Sathiyamoorthy, V. and Lisa, M. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. Vaccines, 3: 1, 2018.